Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 13;26:78. doi: 10.1186/s10020-020-00208-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — ARID1A or ARID1B mutations are tightly associated with sensitivity to immune checkpoint inhibitors (ICIs). a. The comparison of tumor mutational burden (TMB) values and PD-L1 expression grouped by the genomic signatures of ARID1 subunits; b. The correlations between ARID1A or ARID1B expression and the abundances of activated CD8+ T cells and activated dendritic cells (DC) in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC); c. The underlying relationships between prognosis and ARID1A or ARID1B mutation deduced from this research. (**: P<0.01; *: P<0.05)